Trulicity is FDA-approved for improving blood sugar control in adults with type 2 diabetes and reducing the risk of cardiovascular events in type 2 diabetes patients with established cardiovascular disease or multiple cardiovascular risk factors
Safety Profile The adverse-event pattern was the familiar incretin-class signature, gastrointestinal-led, with a dose-dependent discontinuation rate: 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg) discontinued for adverse events, versus 4.9% on placebo
The amount of bacteriostatic water you add determines the concentration of your solution, which in turn determines how many units you draw for each dose
Avoid GLP-1 only if you have a history of Medullary Thyroid Carcinoma (MTC) or MEN2
Common reactions include mild injection-site soreness, flushing, transient nausea, or a temporary body odor from methionine